Our Vision

We aim to redefine what's possible in drug discovery by unlocking the therapeutic potential of synthetic macrocycles (unnatural products) to build a robust, diverse pipeline of valuable medicines.

Leadership

Cameron Pye, PhD Co-Founder & CEO UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggab

Cameron Pye, PhD

Co-Founder & CEO

UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggable.

Joshua Schwochert, PhD Co-Founder & CSO Macrocycle and cyclic peptide expert with a PhD from UC Santa Cruz, whose doctoral collaborations with Pfizer and Eli Lilly on beyond-rule-of-5 pharmacokinetics laid the scientific foundation for UNP

Joshua Schwochert, PhD

Co-Founder & CSO

Macrocycle and cyclic peptide expert with a PhD from UC Santa Cruz, whose doctoral collaborations with Pfizer and Eli Lilly on beyond-rule-of-5 pharmacokinetics laid the scientific foundation for UNP's drug discovery platform.

Neera Ravindran, MD, MBA Chief Financial Officer Finance leader with 20+ years of experience across public markets and private biotech. Previously CFO of Kriya Therapeutics, where she led its $270M Series C; VP of Investor Relations at Vir Bio

Neera Ravindran, MD, MBA

Chief Financial Officer

Finance leader with 20+ years of experience across public markets and private biotech. Previously CFO of Kriya Therapeutics, where she led its $270M Series C; VP of Investor Relations at Vir Biotechnology; and Head of Investor Relations, North America, at Roche/Genentech. Dr. Ravindran holds an M.D. from Kasturba Medical College and an M.B.A. from the Indian School of Business.

Simon Bailey, PhD COO & President of R&D Veteran drug discovery leader with 25+ years of experience across Pfizer, Intercept Pharmaceuticals, and Plexium, and recipient of the ACS Hero of Chemistry award for his role in the discovery o

Simon Bailey, PhD

COO & President of R&D

Veteran drug discovery leader with 25+ years of experience across Pfizer, Intercept Pharmaceuticals, and Plexium, and recipient of the ACS Hero of Chemistry award for his role in the discovery of Lorbrena™

Lindsay Young VP Human Resources Lindsay brings broad experience across the HR landscape—people strategy, compliance, talent acquisition, compensation, and building amazing places to work. Before joining Unnatural Products, Lindsay served as t

Lindsay Young

VP Human Resources

Lindsay brings broad experience across the HR landscape—people strategy, compliance, talent acquisition, compensation, and building amazing places to work. Before joining Unnatural Products, Lindsay served as the Head of Human Resources at Tempest Therapeutics, and earlier in her career she held various positions in commercial operations at Cepheid and CV Therapeutics.

Henry Johnson, PhD VP Medicinal Chemistry and CMC Henry W.B. Johnson, PhD, is a drug discovery leader with 20+ years of experience advancing small molecule therapeutics. He has led multidisciplinary R&D teams and contributed to the advance

Henry Johnson, PhD

VP Medicinal Chemistry and CMC

Henry W.B. Johnson, PhD, is a drug discovery leader with 20+ years of experience advancing small molecule therapeutics. He has led multidisciplinary R&D teams and contributed to the advancement of several clinical assets from early discovery through late-stage development.

Board of Directors

Cameron Pye, PhD UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggable.

Cameron Pye, PhD

UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggable.

Mert Aktar CEO of Receptive Bio and a life sciences executive with over 20 years of experience bridging science and business, having previously served as SVP and Global Head of Corporate Development & Strategy at Kite Pharma. He also holds b

Mert Aktar

CEO of Receptive Bio and a life sciences executive with over 20 years of experience bridging science and business, having previously served as SVP and Global Head of Corporate Development & Strategy at Kite Pharma. He also holds board positions with Kyverna Therapeutics, ReAlta Life Sciences, and the UCLA Technology Development Group.

Abbas Kazimi CEO and board member of Nimbus Therapeutics, a computational drug discovery company, where he previously served as Chief Business Officer and helped drive transactions totaling over $7 billion. He holds a B.A. from the University of

Abbas Kazimi

CEO and board member of Nimbus Therapeutics, a computational drug discovery company, where he previously served as Chief Business Officer and helped drive transactions totaling over $7 billion. He holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University.

Stuart Peterson Founder and Managing Partner of ARTIS Ventures, a San Francisco–based tech-bio venture firm known for early investments in YouTube and Stemcentrx. He has served on numerous life sciences boards, including IDbyDNA and Locus BioSci

Stuart Peterson

Founder and Managing Partner of ARTIS Ventures, a San Francisco–based tech-bio venture firm known for early investments in YouTube and Stemcentrx. He has served on numerous life sciences boards, including IDbyDNA and Locus BioSciences.

William Taranto Founder and President of the Merck Global Health Innovation Fund, Merck's corporate venture arm, which he launched in 2010 and has grown into an evergreen fund with a broad healthcare portfolio. He spent 18 years at Johnson &

William Taranto

Founder and President of the Merck Global Health Innovation Fund, Merck's corporate venture arm, which he launched in 2010 and has grown into an evergreen fund with a broad healthcare portfolio. He spent 18 years at Johnson & Johnson in venture and business development roles before joining Merck.

Nicholas Shekerdemian Founder and Managing Partner of The Venture Collective (TVC), an early-stage venture firm investing at the intersection of deep tech, biotech, and healthcare. A former Thiel Fellow, he previously co-founded and led the AI r

Nicholas Shekerdemian

Founder and Managing Partner of The Venture Collective (TVC), an early-stage venture firm investing at the intersection of deep tech, biotech, and healthcare. A former Thiel Fellow, he previously co-founded and led the AI recruiting startup Headstart.

Luc Dochez Managing Partner of DROIA Genetic Disease Fund and a veteran European biotech entrepreneur and investor with more than 20 years in the industry, best known as former CEO of Tusk Therapeutics, which he led to its acquisition by Roche.

Luc Dochez

Managing Partner of DROIA Genetic Disease Fund and a veteran European biotech entrepreneur and investor with more than 20 years in the industry, best known as former CEO of Tusk Therapeutics, which he led to its acquisition by Roche. He has co-founded multiple companies, including Pharvaris and Vico Therapeutics, and serves as a biotech investor focused on oncology and genetic disease.

Scientific Advisors

Mark Pruzanski CEO Alentis Therapeutics

Mark Pruzanski

CEO Alentis Therapeutics

Larry Mattheakis Former SVP Biology Protagonist

Larry Mattheakis

Former SVP Biology Protagonist

Scott Lokey UCSC Professor and Macrocycle Field Leader

Scott Lokey

UCSC Professor and Macrocycle Field Leader

Tomi Sawyer Peptide Drug Hunter, Ex-Merck

Tomi Sawyer

Peptide Drug Hunter, Ex-Merck

Nancy Thornberry Former CEO Kallyope

Nancy Thornberry

Former CEO Kallyope